Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 132.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 24,815 shares of the company’s stock after purchasing an additional 14,157 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Twist Bioscience were worth $1,153,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of TWST. Vanguard Group Inc. boosted its stake in Twist Bioscience by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after purchasing an additional 189,791 shares during the period. ARK Investment Management LLC boosted its stake in shares of Twist Bioscience by 4.4% during the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after buying an additional 237,772 shares during the period. State Street Corp grew its holdings in shares of Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after buying an additional 526,028 shares during the last quarter. Thrivent Financial for Lutherans increased its position in Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock valued at $69,972,000 after acquiring an additional 532,040 shares during the period. Finally, Geode Capital Management LLC raised its stake in Twist Bioscience by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after acquiring an additional 26,145 shares during the last quarter.

Twist Bioscience Stock Performance

Shares of TWST opened at $41.58 on Friday. The company has a market capitalization of $2.48 billion, a PE ratio of -12.30 and a beta of 2.15. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company has a 50-day simple moving average of $45.30 and a 200-day simple moving average of $45.31. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same period last year, the firm earned ($0.75) EPS. Equities research analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Twist Bioscience news, Director Robert Chess sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the transaction, the director now directly owns 16,641 shares in the company, valued at approximately $832,050. This trade represents a 23.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Emily M. Leproust sold 5,200 shares of Twist Bioscience stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $256,620.00. Following the transaction, the chief executive officer now owns 667,318 shares of the company’s stock, valued at approximately $32,932,143.30. The trade was a 0.77 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,799 shares of company stock valued at $1,593,944. 3.01% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 4th. Finally, Barclays set a $58.00 target price on shares of Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.